BOCA RATON, Fla., Sept. 28, 2012 /PRNewswire/ -- Sensus Healthcare is pleased to announce its exhibitor participation in the 54th Annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston, MA on October 28 - 31, 2012. Visit Booth #9054 to learn more about the advanced SRT-100™ superficial radiotherapy platform, its unique characteristics and advantages over other NMSC treatment modalities, and how it optimally integrates as a dedicated NMSC treatment solution in the radiation therapy department.
"We cordially invite all ASTRO attendees to take this opportunity to visit our booth in the upcoming 54th Annual ASTRO meeting in Boston, MA and rediscover superficial radiotherapy (SRT) as the optimal radiotherapy solution for treating Non-Melanoma Skin Cancer (NMSC) patients. We are proud to feature our contemporary SRT-100™ superficial radiotherapy platform at the meeting and demonstrate to the attendees how they can better their patients' outcomes while contributing to the optimization of their department's workflow, throughput, and operations," stated Joe Sardano, President/CEO, Sensus Healthcare.
About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. SRT-100™ is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam™ characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100™ is FDA, CE, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.
561-922-5808 Ext. 100,p>